Skip to main content

Table 1 Patient characteristicsa

From: Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

Early breast cancer Metastatic breast cancer
Number of patients enrolled = 25 Number of patients enrolled = 25
Age, years Age, years
Median (range), 59 (26 to 76) Median (range), 59 (36 to 83)
ECOG performance status, n (%) ECOG performance status, n (%)
0 24 (96%) 0 8 (32%)
1 1 (4%) 1 13 (52%)
2 0 (0%) 2 4 (16%)
Histology, n (%) Histology, n (%)
Ductal 22 (88%) Ductal 20 (80%)
Lobular 3 (12%) Lobular 1 (4%)
Other 0 (0%) Unknown 4 (16%)
Menopausal status, n (%) Menopausal status, n (%)
Premenopausal 8 (32%) Premenopausal 4 (16%)
Perimenopausal 1 (4%) Perimenopausal 1 (4)
Postmenopausal 16 (64%) Postmenopausal 20 (80%)
Hormone receptor status, n (%) Hormone receptor status, n (%)
ER-positive/PR-positive 11 (44%) ER-positive/PR-positive 11 (44%)
ER-positive/PR-negative 6 (24%) ER-positive/PR-negative 3 (12%)
ER-negative/PR-positive 1 (4%) ER-negative/PR-positive 2 (8%)
ER-negative/PR-negative 7 (28%) ER-negative/PR-negative 9 (36%)
Tumour size, n (%) Number of disease sites, n (%)
1 to 1.9 cm (T1) 6 (24%) 1 7 (28%)
2 to 5 cm (T2) 16 (64%) 2 9 (36%)
>5 cm (T3) 1 (4%) 3 4 (16%)
Unknown 2 (8%) ≥4 5 (20%)
Tumour grade, n (%) Line of treatment, n (%)
I 2 (8%) First 11 (44%)
II 9 (36%) Second 7 (28%)
III 13 (52%) ≥Third 7 (28%)
Unknown 1 (4%)  
  Primary breast cancer at presentation, n (%)
  Early 9 (36%)
Positive nodes, n (%) Metastatic 16 (64%)
0 (N0) 11 (44%)  
1 to 3 (N1) 9 (36%) Visceral disease, n (%)
4 to 9 (N2) 2 (8%) Yes 13 (52%)
≥10 (N3) 2 (8%) No 12 (48%)
  1. aECOG = Eastern Cooperative Oncology Group; ER = oestrogen receptor; PR = progesterone receptor.